The Li Ka Shing Foundation and Temasek Trust are donating histotripsy systems to Singaporean institutes to advance regional cancer research and innovation. Hong Kong’s Li Ka Shing Foundation (LKSF)  and Singapore’s Temasek Trust (TT) have jointly committed S$12 million to bring innovative, non-invasive ultrasound-based cancer treatment to Southeast Asia. The philanthropic organisations are purchasing two histotripsy systems for donation to the National Cancer Centre Singapore (NCCS) and the National University Cancer Institute, Singapore, TT said in a statement. The beneficiaries will use the histotripsy systems, which will be the first in Southeast Asia, for a clinical trial with liver, kidney and pancreatic cancer patients. The trial is slated to begin later this year, with a targeted enrolment of 40 patients. Histotripsy is a non-invasive procedure that produces shock waves to break down tumours at the cellular level without requiring any surgery, incisions or radiation. It offers a painless, scarless, and bloodless treatment to destroy tumours including those that cannot be surgically removed, TT said. The procedure is being clinically used or tried in parts of the world including the United ...